×
About 2,293 results

ALLMedicine™ Bullous Pemphigoid Center

Research & Reviews  771 results

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the Europ...
https://doi.org/10.1111/jdv.18220
Journal of the European Academy of Dermatology and Venere... Borradori L, Van Beek N et. al.

Jun 30th, 2022 - Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesion...

Imputation of the major histocompatibility complex region identifies major independent ...
https://doi.org/10.1111/1346-8138.16499
The Journal of Dermatology; Fan W, Li Z et. al.

Jun 26th, 2022 - As autoimmune skin diseases, both bullous pemphigoid (BP) and dermatomyositis (DM) show significant associations with the major histocompatibility complex (MHC) region. In fact, the coexistence of BP and DM has been previously reported. Therefore,...

Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)
https://clinicaltrials.gov/ct2/show/NCT05061771

Jun 24th, 2022 - A phase III two-part study of nomacopan, a bifunctional inhibitor of complement component C5 and leukotriene B4 (LTB4), for the treatment of moderate and severe bullous pemphigoid. There is evidence that both terminal complement activation (via C5...

Dyshidrotic Eczema (Pompholyx)
https://emedicine.medscape.com/article/1122527-overview

Jun 20th, 2022 - Practice Essentials Dyshidrotic eczema, also termed pompholyx, is a type of eczema (dermatitis). This skin condition is characterized by intensely itchy blisters that develop on the edges of the fingers, toes, palms, and soles of the feet. Dyshidr...

Dyshidrotic Eczema (Pompholyx)
http://emedicine.medscape.com/article/1122527-overview

Jun 20th, 2022 - Practice Essentials Dyshidrotic eczema, also termed pompholyx, is a type of eczema (dermatitis). This skin condition is characterized by intensely itchy blisters that develop on the edges of the fingers, toes, palms, and soles of the feet. Dyshidr...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  44 results

Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)
https://clinicaltrials.gov/ct2/show/NCT05061771

Jun 24th, 2022 - A phase III two-part study of nomacopan, a bifunctional inhibitor of complement component C5 and leukotriene B4 (LTB4), for the treatment of moderate and severe bullous pemphigoid. There is evidence that both terminal complement activation (via C5...

A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.
https://clinicaltrials.gov/ct2/show/NCT04612790

Jun 9th, 2022 - Bullous pemphigoid (BP) is a rare disease mainly affecting the elderly. BP is associated with significant morbidity and increased mortality secondary to increased risk of secondary infections, comorbid conditions, and serious side effects from hig...

A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD)
https://clinicaltrials.gov/ct2/show/NCT05267600

Jun 8th, 2022 - ARGX-113-2009 is an operationally seamless 2-part, phase 2/3, prospective, global, multicenter, randomized, double-blinded, placebo-controlled study to investigate the efficacy, safety, tolerability, immunogenicity, participant-reported outcome me...

Telederm and Bullous Pemphigoid
https://clinicaltrials.gov/ct2/show/NCT04728854

Jun 7th, 2022 - The study team plans to recruit 45 subjects from the autoimmune blistering disease clinic at Emory Dermatology Clinic. The plan is to improve the quality of future clinical trials in bullous pemphigoid (BP), the team will monitor repeated measurem...

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
https://clinicaltrials.gov/ct2/show/NCT04206553

May 26th, 2022 - The primary objective of the study is to demonstrate that dupilumab is superior to placebo in achieving sustained remission off oral corticosteroids (OCS) in patients with bullous pemphigoid (BP). The secondary objectives of the study are: To eval...

see more →

News  96 results

Eosinophilic Diseases Often Overlap, Raising Costs
https://www.medscape.com/viewarticle/974781

May 27th, 2022 - Eosinophilic GI diseases (EGIDs) often overlap with other eosinophil-associated diseases (EADs), which leads to greater health care costs, according to an analysis of the U.S. Optum Clinformatics claims database. EADs have gained increased attenti...

Eosinophilic diseases often overlap, raising costs
https://www.mdedge.com/internalmedicine/article/255002/gastroenterology/eosinophilic-diseases-often-overlap-raising-costs
Jim Kling

May 26th, 2022 - Eosinophilic GI diseases (EGIDs) often overlap with other eosinophil-associated diseases (EADs), which leads to greater health care costs, according to an analysis of the U. S.

Age, Skin Cancer Risks for ICI-Induced Bullous Pemphigoid
https://www.medscape.com/viewarticle/972516

Apr 21st, 2022 - Bullous pemphigoid, an immune-mediated condition chacterized by large, fluid-filled blisters on the skin, is a rare but serious complication of cancer therapy with immune checkpoint inhibitors (ICIs) that may result in treatment interruption or ce...

Blistering Lesions in a Newborn
https://www.mdedge.com/dermatology/article/253884/pediatrics/blistering-lesions-newborn
Gabriella Alvarez, BS, Shivani Shah, DO, MPH et. al.

Apr 19th, 2022 - The Diagnosis: Epidermolysis Bullosa Our patient was found to have epidermolysis bullosa (EB), a rare genetic disease in which the superficial layers of the skin separate to form vesicles or bullae due to a mutation in the keratin 14 gene, KRT14.

Bullous Dermatoses and Quality of Life: A Summary of Tools to Assess Psychosocial Health
https://www.mdedge.com/dermatology/article/251626/practice-management/bullous-dermatoses-and-quality-life-summary-tools
Alexandria Riopelle, MD, Eden Lake, MD

Feb 10th, 2022 - Autoimmune bullous dermatoses (ABDs) develop due to antibodies directed against antigens within the epidermis or at the dermoepidermal junction. They are categorized histologically by the location of acantholysis (separation of keratinocytes), cli.

see more →

Patient Education  5 results see all →